Autoantibody profile during short-term infliximab treatment for Crohn's disease: A prospective cohort study

F. Atzeni, S. Ardizzone, P. Sarzi-Puttini, E. Colombo, G. Maconi, S. De Portu, M. Carrabba, G. Bianchi Porro

Research output: Contribution to journalArticle

Abstract

Background: The potential clinical implications of autoimmunity during treatment with infliximab are unclear. Aim: To determine the frequency and correlation of autoantibody formation in patients with Crohn's disease treated with infliximab in a routine clinical setting. Methods: Sixty-three patients with refractory/inflammatory (31) and/or fistulising Crohn's disease (32), received an infliximab infusion at a dose 5 mg/kg in weeks O, 2 and 6, and were evaluated for the development of antinuclear, anti-double-stranded DNA, anti-Sm, anti-RNP, anti-SSA, anti-SSB and antihistone antibodies. The correlates with pharmacological treatments, the response to infliximab and adverse events were evaluated. Results: Antinuclear antibodies were found in five of the 63 patients (8%) at baseline and in 26 (42%) after 10 weeks (P <0.001). Of the 26 antinuclear antibody-positive patients who were further subtyped, nine of 63 (17%) had anti-double-stranded DNA (P = 0.003), and 1.5% were extractable nuclear antigen (ENA) and antihistone-positive. Five patients were initially positive for anticardiolipin antibodies and two more patients became positive during infliximab treatment. New autoantibody formation was more frequent in the patients with inflammatory/refractory disease than in those with fistulising disease (17 vs. 7; P = 0.02). One patient developed drug-induced lupus without major organ damage. Conclusions: Autoantibody formation occurs in 42% of patients (8% of these patients were positive before infliximab treatment) with Crohn's disease receiving induction treatment with infliximab, but the clinical significance of this remains to be determined.

Original languageEnglish
Pages (from-to)453-461
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume22
Issue number5
DOIs
Publication statusPublished - Sep 1 2005

Fingerprint

Crohn Disease
Autoantibodies
Cohort Studies
Prospective Studies
Therapeutics
Antinuclear Antibodies
Infliximab
Anticardiolipin Antibodies
Nuclear Antigens
DNA
Autoimmunity
Pharmacology
Antibodies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Atzeni, F., Ardizzone, S., Sarzi-Puttini, P., Colombo, E., Maconi, G., De Portu, S., ... Porro, G. B. (2005). Autoantibody profile during short-term infliximab treatment for Crohn's disease: A prospective cohort study. Alimentary Pharmacology and Therapeutics, 22(5), 453-461. https://doi.org/10.1111/j.1365-2036.2005.02576.x

Autoantibody profile during short-term infliximab treatment for Crohn's disease : A prospective cohort study. / Atzeni, F.; Ardizzone, S.; Sarzi-Puttini, P.; Colombo, E.; Maconi, G.; De Portu, S.; Carrabba, M.; Porro, G. Bianchi.

In: Alimentary Pharmacology and Therapeutics, Vol. 22, No. 5, 01.09.2005, p. 453-461.

Research output: Contribution to journalArticle

Atzeni, F, Ardizzone, S, Sarzi-Puttini, P, Colombo, E, Maconi, G, De Portu, S, Carrabba, M & Porro, GB 2005, 'Autoantibody profile during short-term infliximab treatment for Crohn's disease: A prospective cohort study', Alimentary Pharmacology and Therapeutics, vol. 22, no. 5, pp. 453-461. https://doi.org/10.1111/j.1365-2036.2005.02576.x
Atzeni, F. ; Ardizzone, S. ; Sarzi-Puttini, P. ; Colombo, E. ; Maconi, G. ; De Portu, S. ; Carrabba, M. ; Porro, G. Bianchi. / Autoantibody profile during short-term infliximab treatment for Crohn's disease : A prospective cohort study. In: Alimentary Pharmacology and Therapeutics. 2005 ; Vol. 22, No. 5. pp. 453-461.
@article{6ef05d6a99304b6388dd3943192278ee,
title = "Autoantibody profile during short-term infliximab treatment for Crohn's disease: A prospective cohort study",
abstract = "Background: The potential clinical implications of autoimmunity during treatment with infliximab are unclear. Aim: To determine the frequency and correlation of autoantibody formation in patients with Crohn's disease treated with infliximab in a routine clinical setting. Methods: Sixty-three patients with refractory/inflammatory (31) and/or fistulising Crohn's disease (32), received an infliximab infusion at a dose 5 mg/kg in weeks O, 2 and 6, and were evaluated for the development of antinuclear, anti-double-stranded DNA, anti-Sm, anti-RNP, anti-SSA, anti-SSB and antihistone antibodies. The correlates with pharmacological treatments, the response to infliximab and adverse events were evaluated. Results: Antinuclear antibodies were found in five of the 63 patients (8{\%}) at baseline and in 26 (42{\%}) after 10 weeks (P <0.001). Of the 26 antinuclear antibody-positive patients who were further subtyped, nine of 63 (17{\%}) had anti-double-stranded DNA (P = 0.003), and 1.5{\%} were extractable nuclear antigen (ENA) and antihistone-positive. Five patients were initially positive for anticardiolipin antibodies and two more patients became positive during infliximab treatment. New autoantibody formation was more frequent in the patients with inflammatory/refractory disease than in those with fistulising disease (17 vs. 7; P = 0.02). One patient developed drug-induced lupus without major organ damage. Conclusions: Autoantibody formation occurs in 42{\%} of patients (8{\%} of these patients were positive before infliximab treatment) with Crohn's disease receiving induction treatment with infliximab, but the clinical significance of this remains to be determined.",
author = "F. Atzeni and S. Ardizzone and P. Sarzi-Puttini and E. Colombo and G. Maconi and {De Portu}, S. and M. Carrabba and Porro, {G. Bianchi}",
year = "2005",
month = "9",
day = "1",
doi = "10.1111/j.1365-2036.2005.02576.x",
language = "English",
volume = "22",
pages = "453--461",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Autoantibody profile during short-term infliximab treatment for Crohn's disease

T2 - A prospective cohort study

AU - Atzeni, F.

AU - Ardizzone, S.

AU - Sarzi-Puttini, P.

AU - Colombo, E.

AU - Maconi, G.

AU - De Portu, S.

AU - Carrabba, M.

AU - Porro, G. Bianchi

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Background: The potential clinical implications of autoimmunity during treatment with infliximab are unclear. Aim: To determine the frequency and correlation of autoantibody formation in patients with Crohn's disease treated with infliximab in a routine clinical setting. Methods: Sixty-three patients with refractory/inflammatory (31) and/or fistulising Crohn's disease (32), received an infliximab infusion at a dose 5 mg/kg in weeks O, 2 and 6, and were evaluated for the development of antinuclear, anti-double-stranded DNA, anti-Sm, anti-RNP, anti-SSA, anti-SSB and antihistone antibodies. The correlates with pharmacological treatments, the response to infliximab and adverse events were evaluated. Results: Antinuclear antibodies were found in five of the 63 patients (8%) at baseline and in 26 (42%) after 10 weeks (P <0.001). Of the 26 antinuclear antibody-positive patients who were further subtyped, nine of 63 (17%) had anti-double-stranded DNA (P = 0.003), and 1.5% were extractable nuclear antigen (ENA) and antihistone-positive. Five patients were initially positive for anticardiolipin antibodies and two more patients became positive during infliximab treatment. New autoantibody formation was more frequent in the patients with inflammatory/refractory disease than in those with fistulising disease (17 vs. 7; P = 0.02). One patient developed drug-induced lupus without major organ damage. Conclusions: Autoantibody formation occurs in 42% of patients (8% of these patients were positive before infliximab treatment) with Crohn's disease receiving induction treatment with infliximab, but the clinical significance of this remains to be determined.

AB - Background: The potential clinical implications of autoimmunity during treatment with infliximab are unclear. Aim: To determine the frequency and correlation of autoantibody formation in patients with Crohn's disease treated with infliximab in a routine clinical setting. Methods: Sixty-three patients with refractory/inflammatory (31) and/or fistulising Crohn's disease (32), received an infliximab infusion at a dose 5 mg/kg in weeks O, 2 and 6, and were evaluated for the development of antinuclear, anti-double-stranded DNA, anti-Sm, anti-RNP, anti-SSA, anti-SSB and antihistone antibodies. The correlates with pharmacological treatments, the response to infliximab and adverse events were evaluated. Results: Antinuclear antibodies were found in five of the 63 patients (8%) at baseline and in 26 (42%) after 10 weeks (P <0.001). Of the 26 antinuclear antibody-positive patients who were further subtyped, nine of 63 (17%) had anti-double-stranded DNA (P = 0.003), and 1.5% were extractable nuclear antigen (ENA) and antihistone-positive. Five patients were initially positive for anticardiolipin antibodies and two more patients became positive during infliximab treatment. New autoantibody formation was more frequent in the patients with inflammatory/refractory disease than in those with fistulising disease (17 vs. 7; P = 0.02). One patient developed drug-induced lupus without major organ damage. Conclusions: Autoantibody formation occurs in 42% of patients (8% of these patients were positive before infliximab treatment) with Crohn's disease receiving induction treatment with infliximab, but the clinical significance of this remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=24344450107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24344450107&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2005.02576.x

DO - 10.1111/j.1365-2036.2005.02576.x

M3 - Article

C2 - 16128684

AN - SCOPUS:24344450107

VL - 22

SP - 453

EP - 461

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -